Last reviewed · How we verify
Typhim Vi (Sanofi Pasteur MSD)
Typhim Vi is an inactivated typhoid vaccine that stimulates the immune system to produce antibodies against Salmonella typhi polysaccharide antigen.
Typhim Vi is an inactivated typhoid vaccine that stimulates the immune system to produce antibodies against Salmonella typhi polysaccharide antigen. Used for Active immunization against typhoid fever caused by Salmonella typhi.
At a glance
| Generic name | Typhim Vi (Sanofi Pasteur MSD) |
|---|---|
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Drug class | Inactivated bacterial vaccine |
| Target | Salmonella typhi Vi polysaccharide antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains purified Vi polysaccharide capsular antigen from Salmonella typhi, which is conjugated to tetanus toxoid to enhance immunogenicity. Upon administration, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies against typhoid fever. This provides active immunization against infection with Salmonella typhi.
Approved indications
- Active immunization against typhoid fever caused by Salmonella typhi
Common side effects
- Injection site pain or erythema
- Headache
- Myalgia
- Fever
- Malaise
Key clinical trials
- Polysaccharide Antibody Response Study (PHASE4)
- Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |